Work

Supplementary Figure from Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure from Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

DOI: 10.1158/1078-0432.22487760.v1

Authors: Maria R. Baer, Aksinija A. Kogan, Søren M. Bentzen, Tian Mi, Rena G. Lapidus, Vu H. Duong, Ashkan Emadi, Sandrine Niyongere, Casey L. O'Connell, Benjamin A. Youngblood, Stephen B. Baylin, Feyruz V. Rassool

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361940901

Cites:

Cited by:

Related to: 10